BICO Group Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Maria Forss

Algemeen directeur

SEK 7.4m

Totale compensatie

Percentage CEO-salaris	6.5%
Dienstverband CEO	less than a year
Eigendom CEO	0.06%
Management gemiddelde ambtstermijn	1.7yrs
Gemiddelde ambtstermijn bestuur	4.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Maria Forss's beloning veranderd ten opzichte van BICO Group's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-SEK 2b
Jun 30 2024	n/a	n/a	-SEK 1b
Mar 31 2024	n/a	n/a	-SEK 2b
Dec 31 2023	SEK 7m	SEK 484k	-SEK 2b

Compensatie versus markt: De totale vergoeding ($USD 679.67K ) Maria } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 852.77K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Maria te vergelijken met de prestaties van het bedrijf.

CEO

Maria Forss (52 yo)

less than a year

Tenure

SEK 7,425,520

Compensatie

Ms. Maria Forss serves as President & CEO of BICO Group AB (publ) since November 20, 2023. She served as Senior Vice President of Consumables at Vitrolife AB (publ) since January 01, 2022 until August 2023...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Maria Forss	President & CEO	less than a year	SEK 7.43m	0.057% € 116.8k
Jacob Thordenberg	Group Chief Financial Officer	1.8yrs	geen gegevens	0.026% € 53.7k
Marius Balger	Chief Operating Officer	1.7yrs	geen gegevens	geen gegevens
Asa Hillsten	Senior VP & Head of Investor Relations	no data	geen gegevens	geen gegevens
Andreas Joersjo	General Counsel	less than a year	geen gegevens	geen gegevens
Artur Aira	Head of Corporate Development and M&A	1.7yrs	SEK 150.00k	geen gegevens
Catharina Nordlund	Global Head of Human Resources	less than a year	geen gegevens	geen gegevens
Itedale Redwan	Chief Scientific Officer - Bioprinting	no data	geen gegevens	geen gegevens
Niclas Emanuelsson	Head of Global Operations	4.8yrs	geen gegevens	geen gegevens
Holger Eickhoff	Senior VP & Business Area Director - Bioautomation	2.8yrs	geen gegevens	geen gegevens
Erica Bell	Senior VP & Chief People Officer	no data	geen gegevens	geen gegevens
Nicolas Gabriel-Robez	Chief Security Officer	no data	geen gegevens	geen gegevens

1.7yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 49Z wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Rolf Classon	Independent Chairman of the Board	2.6yrs	SEK 650.00k	0.044% € 90.4k
Christian Wildmoser	Independent Director	4.9yrs	SEK 285.00k	0.45% € 928.6k
Robert Langer	Member of Scientific Advisory Board	4yrs	geen gegevens	geen gegevens
Helena Skantorp	Independent Director	4.9yrs	SEK 350.00k	0.0057% € 11.7k
Ulrika Dellby	Independent Deputy Chairwoman	2.6yrs	SEK 510.00k	0.027% € 55.4k
Bengt Sjoholm	Independent Director	8.8yrs	SEK 285.00k	0.49% € 1.0m
Susan Tousi	Independent Director	3yrs	SEK 250.00k	geen gegevens
Ali Khademhosseini	Member of Scientific Advisory Board	7.7yrs	geen gegevens	geen gegevens
Ido Amit	Member of Scientific Advisory Board	4.3yrs	geen gegevens	geen gegevens
Alexandra Gatzemeyer	Director	less than a year	geen gegevens	geen gegevens

4.1yrs

Gemiddelde duur

66.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 49Z wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).

BICO Group Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

BICO Group AB (publ), Annual General Meeting, May 08, 2025

BICO Group AB Announces Management Changes

BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of Directors

BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024

BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of Directors

BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HR

Recent updates

Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million.

Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million.

Forecast to breakeven in 2026

BICO Group AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025

BICO Group AB (publ), Annual General Meeting, May 08, 2025

Second quarter 2024 earnings released: kr1.10 loss per share (vs kr12.73 loss in 2Q 2023)

BICO Group AB Announces Management Changes

New minor risk - Profitability

No longer forecast to breakeven

BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of Directors

First quarter 2024 earnings released: kr0.40 loss per share (vs kr1.67 loss in 1Q 2023)

BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024

BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of Directors

BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

BICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024

Full year 2023 earnings released: kr24.05 loss per share (vs kr12.94 loss in FY 2022)

BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HR

Third quarter 2023 earnings released: kr1.00 loss per share (vs kr1.04 profit in 3Q 2022)

Group Chief Financial Officer recently bought €75k worth of stock

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024

Second quarter 2023 earnings released: kr12.73 loss per share (vs kr0.68 profit in 2Q 2022)

BICO Group AB (publ) Announces Chief Executive Officer Changes

Beos Light Industrial Germany 1 Fund, a fund managed by BEOS AG agreed to acquire property on Wagner-Régeny-Straße 15 from BICO Group AB (publ) (OM:BICO) for €21 million.

BICO Group AB (publ) Elects Gerry Mackay to Its Board of Directors

First quarter 2023 earnings released: kr1.67 loss per share (vs kr0.68 loss in 1Q 2022)

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Now 39% undervalued after recent price drop

Independent Chairman of the Board recently sold €747k worth of stock

BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023

BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFO

BICO Group AB (publ) to Report Q1, 2023 Results on May 04, 2023

High number of new and inexperienced directors

Third quarter 2022 earnings released

BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023

BICO Group Announces Appointment of Nomination Committee 2023

Forecast breakeven date moved forward to 2022

Second quarter 2022 earnings released

Forecast breakeven date moved forward to 2022

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2023

BICO Group Adds Åsa Hillsten as SVP and Head of IR

BICO Group AB (publ) (OM : BICO) acquired Allegro 3D for $11 million.

BICO (publ) Appoints Mikael Engblom as Interim CFO

High number of new and inexperienced directors

BICO Group AB (Publ) Announces Board Appointments

Co-Founder recently bought €94k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

BICO Reaches Beneficial and Sustainable Solution with Organovo

DISPENDIX, A BICO Company, Announces That the I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler will be introduced at SLAS 2022

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

Co-Founder recently bought €1.9m worth of stock

BICO Group AB (publ) (OM:BICO) agreed to acquire Biosero Llc.

Third quarter 2021 earnings released

Insider recently sold €1.1m worth of stock

BICO Group AB (publ) (OM:BICO) acquired all outstanding shares in Advanced BioMatrix, Inc. for $18 million.

CEO & Director recently sold €17m worth of stock

Second quarter 2021 earnings released: kr0.89 loss per share (vs kr0.58 loss in 2Q 2020)

CELLINK Receives Patent for Robotic Systems for Personalized and Automated Aesthetic Medical Procedures

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Discover Echo Inc.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Nanoscribe GmbH for approximately €37 million.

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for €34 million.

First quarter 2021 earnings released

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire MatTek Corporation for $68 million.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Ginolis Ltd from Verso Fund II of Verso Capital Oy, Finnvera plc and Innovestor Ventures for €65.7 million.

Cellink AB (publ) to Report Fiscal Year 2021 Results on Mar 16, 2022

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Ginolis Ltd for €70 million.

New 90-day high: €28.85

Cellink AB (publ) Announces Distribution Agreement Including New Products for Single-Cell RNA Sequencing and NGS Library Preparation

Cellink Announces Third Year Extension of Collaboration with A Global Biopharmaceutical Company for Drug Discovery

New 90-day high: €28.35